Spectrum: Local Antimicrobial Stewardship, for Alberta Children's Hospital

Clindamycin

C. diff Risk

High

Oral Bioavailability

Excellent

Approximate Cost

IV-$18/d PO-$2/d

Spectrum Of Activity

General Spectrum of Activity

Spectrum Of Activity

General Spectrum of Activity

Antibiogram Data

Dosing

Hepatic

Use caution with severe hepatic impairment.

Neonatal

General Pediatric

PO 10-40 mg/kg/DAY divided q6-8h. Max: 2700 mg/DAY.

IV/IM 10-40mg/kg/DAY divided q6-8h. Max: 2700mg/DAY.

General Information

Common Usage

Common Usage

Anaerobic infections above the diaphragm, especially dental infection.

Gram positive skin and soft tissue infections including necrotizing fasciitis as an adjunctive agent to a beta lactam for reducing toxin production.

Skin & soft tissue infections involving susceptible MRSA.

Susceptible infections and surgical prophylaxis in setting of IgE mediated beta-lactam allergy.

For decreasing toxin production in toxic shock syndrome.

Drug Monitoring

Drug Monitoring

Monitor for diarrhea, CBC, hepatic & renal function.

If severe diarrhea, consider C.diff infection.

Adverse Effects

Adverse Effects

Allergy (immediate & delayed), GI upset, diarrhea, cytopenia, abnormal liver enzymes, pseudomembranous colitis.

Additional Information

Additional Information

Some preparations of Clindamycin injection contain benzyl alcohol, which has caused gasping syndrome in neonates.

Pharmacology

Pharmacology

Antimicrobial class: Lincosamide

Average serum half life:

  • Premature neonates: 8.7 hours

  • Full term neonates: 3.6 hours.

  • Infants 1 month to 1 year: 3 hours.

  • Children and Adults: 2-3 hours

Route of Elimination: Mostly hepatic metabolism. 10% of an oral dose excreted in urine and 3.6% excreted in feces as active drug and metabolites.